Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
NEW YORK, March 24, 2017 -- Pomerantz LLP announces that a class action lawsuit has been filed against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (NASDAQ:STML) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 17-cv-00940, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Stemline securities: (1) pursuant and/or traceable to Stemline’s secondary public offering on or about January 20, 2017 (the “Offering”); and/or (2) on the open market between January 19, 2017 and February 1, 2017, inclusive (the “Class Period”). Plaintiff seeks to recover compensable damages caused by Defendants’ violations of the federal securities laws under the Securities Act of 1933 (the “Securities Act”) and under the Securities Exchange Act of 1934 (the “Exchange Act”).
If you are a shareholder who purchased Stemline securities during the Class Period, you have until April 4, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.
[Click here to join this class action]
Stemline is a clinical stage biopharmaceutical company that focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States. Stemline is presently conducting an ongoing pivotal Phase 2 trial in blastic plasmacytoid dendritic cell neoplasm, using Stemline’s experimental compound, SL-401. At present, BPDCN has no approved treatment.
On January 20, 2017, Stemline commenced a Secondary Public Offering, offering 4.5 million shares of its common stock at $10.00 per share, with expected gross proceeds to Stemline of $45 million.
The Complaint alleges that in the offering documents for the Secondary Public Offering and throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: Stemline officials failed to disclose that a cancer patient in one of its trials died from a severe side effect due to SL-401 on January 18, 2017, immediately prior to the Company’s Secondary Public Offering.
On February 2, 2017, before the market opened, The Street published an article entitled “Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial, the Company Raises Money,” revealing that on January 18, 2017, immediately prior to Stemline’s Offering, a cancer patient in a Stemline clinical trial tied to SL-401 died from a severe side effect.
On February 2, 2017, Stemline issued a press release entitled “Stemline Therapeutics Provides Update on Pivotal BPDCN Trial,” confirming the patient’s death.
On this news, Stemline’s share price fell $4.15, or approximately 42.5%, to close at $5.60 on February 2, 2017, damaging investors.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT: Robert S. Willoughby Pomerantz LLP [email protected]
